JP2009534367A5 - - Google Patents

Download PDF

Info

Publication number
JP2009534367A5
JP2009534367A5 JP2009505965A JP2009505965A JP2009534367A5 JP 2009534367 A5 JP2009534367 A5 JP 2009534367A5 JP 2009505965 A JP2009505965 A JP 2009505965A JP 2009505965 A JP2009505965 A JP 2009505965A JP 2009534367 A5 JP2009534367 A5 JP 2009534367A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
treatment
composition according
agonist
functional muscarinic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009505965A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009534367A (ja
Filing date
Publication date
Priority claimed from GBGB0607952.9A external-priority patent/GB0607952D0/en
Application filed filed Critical
Publication of JP2009534367A publication Critical patent/JP2009534367A/ja
Publication of JP2009534367A5 publication Critical patent/JP2009534367A5/ja
Pending legal-status Critical Current

Links

JP2009505965A 2006-04-21 2007-04-23 前駆症状症候群の治療にm1/m4ムスカリン性アゴニスト(サブコメリン)を用いる単独及び組合せ療法 Pending JP2009534367A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0607952.9A GB0607952D0 (en) 2006-04-21 2006-04-21 Novel treatment
PCT/GB2007/001463 WO2007125287A1 (en) 2006-04-21 2007-04-23 Mono and combination therapy with m1/m4 muscarinic agonist (sabcomeline) for treatment of prodromal syndrome

Publications (2)

Publication Number Publication Date
JP2009534367A JP2009534367A (ja) 2009-09-24
JP2009534367A5 true JP2009534367A5 (enExample) 2010-06-17

Family

ID=36581049

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009505965A Pending JP2009534367A (ja) 2006-04-21 2007-04-23 前駆症状症候群の治療にm1/m4ムスカリン性アゴニスト(サブコメリン)を用いる単独及び組合せ療法

Country Status (7)

Country Link
US (1) US20090318414A1 (enExample)
EP (1) EP2012783A1 (enExample)
JP (1) JP2009534367A (enExample)
CN (1) CN101472586A (enExample)
CA (1) CA2649590A1 (enExample)
GB (1) GB0607952D0 (enExample)
WO (1) WO2007125287A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3061821B1 (en) 2009-07-22 2019-07-10 Puretech Health LLC Compositions for treatment of disorders ameliorated by muscarinic receptor activation
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
TWI664165B (zh) 2014-04-23 2019-07-01 日商武田藥品工業股份有限公司 含氮雜環化合物
KR20180019234A (ko) 2015-06-26 2018-02-23 다케다 야쿠힌 고교 가부시키가이샤 콜린성 무스카린 m1 수용체의 조절제로서의 2,3-디히드로-4h-1,3-벤족사진-4-온 유도체
JP6787913B2 (ja) 2015-10-20 2020-11-18 武田薬品工業株式会社 複素環化合物
IL281809B (en) 2018-09-28 2022-09-01 Karuna Therapeutics Inc Compositions and methods for the treatment of diseases improved by the activation of muscarinic receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48315A1 (en) * 1989-04-13 1998-04-17 Beecham Group Plc Novel compounds
GB0008921D0 (en) * 2000-04-11 2000-05-31 Smithkline Beecham Plc Method of treatment
US20010036949A1 (en) * 2000-05-09 2001-11-01 Coe Jotham Wadsworth Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
JP2004502665A (ja) * 2000-06-30 2004-01-29 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病を治療する化合物
US20040023951A1 (en) * 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
NZ533566A (en) * 2001-12-28 2007-03-30 Acadia Pharm Inc Tetrahydroquinoline analogues as muscarinic agonists
GB0428180D0 (en) * 2004-12-23 2005-01-26 Biopartners Ltd Combination therapy

Similar Documents

Publication Publication Date Title
Lara et al. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression
Malhotra et al. Nicotine and periodontal tissues
CN101772346B (zh) 用于降低治疗副作用的方法和组合物
JP2022180461A5 (enExample)
JP6099609B2 (ja) 肺炎症を低減するためのレボフロキサシンの吸入
JP2010525050A5 (enExample)
WO2018136554A1 (en) Use of neurokinin-1 antagonists as antitussives
RU2019100425A (ru) Новая доза и препаративная форма
JP2014528474A5 (enExample)
ME02662B (me) Niskofrekventna terapija glatiramer acetatom
AR065579A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
JP2010522137A5 (enExample)
SI2501234T1 (en) Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
PL2043637T3 (pl) Sposoby i leki do podawania ibuprofenu
JP2013541583A5 (enExample)
JP2005508963A5 (enExample)
JP2016505050A5 (enExample)
JP2011500589A5 (enExample)
JP2019514990A5 (enExample)
RU2011111792A (ru) Применение парацетамола и ибупрофена в лечении
JP2008534663A (ja) 慢性的な痛みおよび疲労を特徴とする症候群の治療のためのネフォパムおよびその類似体の使用
JP2006508994A5 (enExample)
CA2506962A1 (en) Synergistic combination comprising roflumilast and formoterol
JP2013513579A5 (enExample)